Johnson & Johnson (NYSE:JNJ) issued an update on its FY21 earnings guidance on Wednesday morning. The company provided earnings per share guidance of $9.60-9.70 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $9.55. The company issued revenue guidance of $92.5-93.3 billion, compared to the consensus revenue estimate of $92.55 billion.Johnson & Johnson also updated its FY 2021 guidance to $9.600-$9.700 EPS.
Shares of JNJ traded up $0.84 during midday trading on Thursday, hitting $170.33. The stock had a trading volume of 253,334 shares, compared to its average volume of 6,223,537. The stock has a market capitalization of $448.55 billion, a price-to-earnings ratio of 30.07, a PEG ratio of 2.71 and a beta of 0.71. Johnson & Johnson has a 1 year low of $133.65 and a 1 year high of $173.65. The company’s 50 day moving average is $167.25. The company has a current ratio of 1.28, a quick ratio of 1.04 and a debt-to-equity ratio of 0.46.
Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, July 20th. The company reported $2.48 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.29 by $0.19. The company had revenue of $23.31 billion for the quarter, compared to the consensus estimate of $22.54 billion. Johnson & Johnson had a net margin of 17.95% and a return on equity of 34.62%. The firm’s revenue was up 27.1% compared to the same quarter last year. During the same quarter last year, the firm posted $1.67 EPS. As a group, sell-side analysts predict that Johnson & Johnson will post 9.51 earnings per share for the current year.
Several research analysts recently commented on JNJ shares. Credit Suisse Group set a $193.00 price target on shares of Johnson & Johnson and gave the stock a buy rating in a research note on Monday, June 7th. Morgan Stanley initiated coverage on shares of Johnson & Johnson in a research note on Friday, May 28th. They issued an overweight rating and a $187.00 price target on the stock. Two equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The company currently has a consensus rating of Buy and an average target price of $190.38.
A hedge fund recently bought a new stake in Johnson & Johnson stock. OLD Mission Capital LLC purchased a new stake in Johnson & Johnson (NYSE:JNJ) during the third quarter, according to its most recent 13F filing with the SEC. The firm purchased 2,432 shares of the company’s stock, valued at approximately $362,000. 66.60% of the stock is owned by institutional investors.
About Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.
Featured Story: Analyst Ratings
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.